In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 records · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Natural fragment Kisspeptin-10 | ||
|---|---|---|---|
| Identity | |||
| Kind | Small molecule | Natural fragment | |
| Area | Sexual health and hormones | Sexual health and hormones | |
| Evidence | |||
| Amount of evidence | 153 | 1,457 (plus 233 on natural levels, listed separately) | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 18 (5 in people) | 31 (0 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 25 | 17 · 3 active1 more mentions it but does not test it | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 21 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Enclomiphene | Kisspeptin-10 |
|---|---|---|
| Sex hormones and fertilityReproductive and sexual health | 89324017 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026).
| Receptor activity and mechanismWhole body | 351916 | 24214218910 |
|---|
| Tumor growthCancer | 725 | 49544 |
|---|
| LipidsMetabolic and weight | 11 | 29920 |
|---|
| Adverse eventsWhole body | 55 | 651 |
|---|
| Growth hormone and IGF-1Endocrine and hormones | 211 | 20812 |
|---|
| Bone and jointMusculoskeletal | 211 | 16115 |
|---|
| PharmacokineticsPharmacology | 66 | 651 |
|---|
| Kidney functionKidney and urinary | 11 | 1010 |
|---|
| Stress hormonesEndocrine and hormones | 22 | 33 |
|---|
| Thyroid functionEndocrine and hormones | 11 | 431 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Kisspeptin-10 is the same as Kisspeptin-54 (metastin) residues 45 to 54, with 1 added group.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Enclomiphene | Kisspeptin-10 |
|---|---|---|
| Sex hormones and fertilityEndocrine and hormonesCompared as: value in the arm that got the peptide, in iu/l | No comparable result 22 randomized-trial results measure it in another way or another unit. | 9 IU/l LH · kisspeptin-10 Vehicle: 3.5 IU/l Dose studied: 4 µg/kg/h7 hn = 82020 |
No comparable result
22 randomized-trial results measure it in another way or another unit.
9 IU/l
LH · kisspeptin-10
Vehicle: 3.5 IU/l
Dose studied: 4 µg/kg/h7 hn = 82020
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 25 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Repros Therapeutics Inc.499 participantsMay 2012 to Oct 2013
Secondary Hypogonadism
Repros Therapeutics Inc.181 participantsNov 2012 to Sept 2013
Secondary Hypogonadism
Repros Therapeutics Inc.151 participantsAug 2012 to Mar 2013
Secondary Hypogonadism
Top 3 of 17 trials, ranked by phase, then posted results and enrollment: 3 completed · source ClinicalTrials.gov (opens in a new tab)
Ghulam Nabi30 participants26 Jun 2014 to 5 Mar 2015
Reproductive Physiological Phenomena
Quaid-e-Azam University15 participants8 Aug 2014 to 5 Mar 2015
Sterility, Reproductive
Quaid-e-Azam University14 participants29 Oct 2013 to 10 Jan 2014
Kisspeptin Action on Insulin in Healthy Normal Men · Kisspeptin Action on Insulin in Obese Diabetic Men
1 more mentions it but does not test it. They only measure it or name it in their text.